The EPS miss and widening loss are bearish, but the $115M convertible offering and positive OCU410 Phase 2 data provide a floor. Watch for Phase 3 trial initiations (OCU410 in H2 2026) and BLA submission timelines (OCU400 by Q2 2027). The stock may trade on clinical catalysts rather than near-term financials.
OCGN drugs
OCGN drug pipeline →Price Chart
Executive Summary
Ocugen reported Q1 2026 EPS of -$0.06, a 16.1% miss vs consensus of -$0.05, with revenue of $1.53M (in line). The miss was offset by positive clinical data (OCU410 Phase 2 GA trial showing 31% lesion reduction) and a $115M convertible note offering that extends cash runway into 2028, but the EPS miss and widening operating loss (-$17.8M vs -$14.5M YoY) are near-term headwinds.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.06 vs consensus -$0.05 (16.1% miss)
- Q1 2026 revenue $1.53M vs consensus $358K (beat, but revenue is immaterial at ~$626M market cap)
- Operating loss widened to -$17.8M from -$14.5M YoY
- Cash, equivalents, and restricted cash $32.2M as of March 31, 2026
- Closed $115M convertible note offering (6.75%, due 2034) expected to extend cash runway into 2028
- Positive 12-month OCU410 Phase 2 data: 31% lesion reduction (p<0.05) in GA; 20% of patients showed no progression
- Phase 3 liMeliGhT trial for RP fully enrolled (N=140); topline data expected Q1 2027
- BLA submissions planned: OCU400 by Q2 2027, OCU410ST by mid-2027, OCU410 by 2028
- 338.3M shares outstanding as of March 31, 2026
Financial Impact
EPS miss of 16.1% vs consensus; operating loss increased $3.3M YoY; $115M convertible offering provides runway into 2028 but adds ~$7.8M annual interest expense
Risk Factors
- EPS miss and widening operating loss signal deteriorating near-term profitability
- Convertible note adds $7.8M annual interest expense and potential dilution if converted
- Clinical trial failures or regulatory delays could impair pipeline value
- High cash burn rate ($19.4M operating expenses in Q1) may require further financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287702 |
Track record
23 reports on OCGN
3 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +20.49% at T+20 after the Jun 11, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
- Nov 10, 20266d ago Press Release Neutral 4/10 Entry $0.9500 to $0.9604 Now $0.7730 −18.63% ▲ +1.09% −0.22% vs SPY
- Nov 6, 202610d ago DEFA14A Neutral 2/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
- Nov 6, 202610d ago DEFA14A Neutral 3/10 Entry $0.9721 to $0.9500 Now $0.7730 −20.48% ▼ −2.27% −1.91% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $0.8745 to $0.8165 Now $0.7730 −11.61% ▼ −6.63% −2.22% vs SPY
- Oct 15, 20264w ago 8-K Neutral 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
- Oct 14, 20264w ago 8-K Mixed 5/10 Entry $0.8137 to $0.7803 Now $0.7730 −5.00% ▼ −4.10% −3.00% vs SPY
- Oct 9, 20265w ago 144 Neutral 2/10 Entry $0.9472 to $0.8854 Now $0.7730 −18.39% ▼ −6.52% −6.51% vs SPY
- Sep 1, 202610w ago Press Release Bullish 7/10 Entry $1.33 to $1.32 Now $0.7730 −41.88% ▼ −0.75% −1.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers